Protara Therapeutics (TARA) Retained Earnings (2013 - 2026)

Protara Therapeutics (TARA) has reported Retained Earnings for 14 consecutive years, with $501.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings rose 20.82% year-over-year to $501.7 million; the TTM figure through Mar 2026 stood at $501.7 million (up 20.82% YoY), while the FY2025 annual figure was $90000.0, down 99.98% from the prior year.
• Retained Earnings improved to $501.7 million in Q1 2026 per TARA's latest filing, from $90000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $501.7 million in Q1 2026 and bottomed at -$285.1 million in Q3 2025.
• Historically, Retained Earnings has averaged $60.2 million across 5 years, with a median of -$165000.0 in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings slumped 63782.32% — and 2024, when it surged 190373.94%.
• Protara Therapeutics' Retained Earnings stood at -$160.0 million in 2022, then decreased by 25.27% to -$200.4 million in 2023, then jumped by 305.64% to $412.1 million in 2024, then sank by 99.98% to $90000.0 in 2025, then jumped by 557364.44% to $501.7 million in 2026.
• Business Quant data shows TARA's Retained Earnings at $501.7 million in Q1 2026, $90000.0 in Q4 2025, and -$285.1 million in Q3 2025.